The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs). https://t.co/RNWrLR53Wx https://t.co/mMmKKrX9vx